Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU

NCT ID: NCT01010087

Last Updated: 2011-06-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 59 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-11-30
• Study Completion Date: 2011-05-31

Brief Summary

Primary Objectives:

The primary objective of the trial is to compare the antiviral efficacy of a 10 day course of standard (75 mg bid) and high-dose (225 mg bid) oseltamivir (or equivalent doses in mild-moderate renal failure) in the treatment of severe influenza infections.

The hypothesis is that high dose oseltamivir will increase the proportion of patients with negative reverse transcriptase (RT)-PCR detection of influenza viral RNA (and viral culture, at selected sites) at Day 5 post-treatment.

An important secondary objective of the trial, which reflects the main clinical objective, is to determine the difference in the numbers of ventilator days between the standard-dose and high-dose groups

Detailed Description

Primary Objectives:

The primary objective of the trial is to compare the antiviral efficacy of a 10 day course of standard (75 mg bid) and high-dose (225 mg bid) oseltamivir (or equivalent doses in mild-moderate renal failure) in the treatment of severe influenza infections.

The hypothesis is that high dose oseltamivir will increase the proportion of patients with negative reverse transcriptase (RT)-PCR detection of influenza viral RNA (and viral culture, at selected sites) at Day 5 post-treatment.

An important secondary objective of the trial, which reflects the main clinical objective, is to determine the difference in the numbers of ventilator days between the standard-dose and high-dose groups.

Secondary Objectives:

• Laboratory objectives:

1. Assess viral RNA load and clearance from nasopharyngeal and tracheal aspirate (intubated) or oropharyngeal (non-intubated) samples by RT-PCR on days 1, 3, 5, 7, 10, 14 and 28 days

2. Determine viral clearance by culture from nasopharyngeal and tracheal aspirate (intubated) or oropharyngeal (non-intubated) samples on days 1, 3, 5, 7, 10, 14 and 28 days at select hospital sites with culture capability

3. Assess the pharmacokinetics of oseltamivir carboxylate and phosphate on Day 3 in suspected H1N1 patients with respiratory distress and/or critical illness requiring ICU care

4. Characterize the inflammatory cytokine response on Day 1-3, 5, 7, 10, 14, 21 and 28 days to severe influenza stratified by standard-dose versus high-dose oseltamivir therapy.

5. Assess leukocyte gene expression at day 1, 3, 5, 10 and 21 days using high throughput RNA assessment techniques

6. Examine urine for biomarkers of disease and severe disease

• Clinical and Safety Objectives:

1. Determine the difference in the number of ventilator days in the standard-dose and high-dose groups

2. Determine tolerability of high-dose versus standard-dose oseltamivir as assessed by the number of serious, atypical and drug-related adverse events that are possibly or probably related to oseltamivir

3. Assess other secondary efficacy variables including survival duration, hospital free days to day 60, ICU free days to day 60, and shock (ie vasopressor) and renal failure free (ie not requiring hemodialysis; ultrafiltration acceptable) days to day 28 in relation to high vs standard dose oseltamivir therapy

4. Assess 60 day mechanical ventilation and ICU-free days stay in relation to high vs standard dose oseltamivir therapy

5. Determine clinical criteria used by clinicians when electing to continue or re-initiate oseltamivir therapy beyond 10 study day treatment course

Tertiary Objectives: Exploratory Analyses

• Laboratory Objectives:

1. Assess the relationship between pharmacokinetic variables on day 3 and measures of viral clearance

2. Assess the frequency and genetic basis of antiviral resistance to oseltamivir during and after therapy

3. Determine possible host genetic factors including HLA type that predispose to severe influenza

• Clinical and Safety Objectives:

1. Determine differences in development and persistence of adverse clinical signs (fever, heart rate, hypotension), requirement for and duration of organ support (supplemental oxygen, vasopressor/inotropes, continuous renal replacement therapy) and occurrence and resolution of organ failure by Sequential Organ Failure Assessment (SOFA) score at days 7, 10, 14 and 28 as a consequence of high-dose versus standard-dose oseltamivir

2. Determine impact of oseltamivir dosing on frequency of progression to mechanical ventilation among non-ventilated patients

Conditions

Influenza A Virus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Standard Oseltamivir dose 75 mg bid

Standard dosing

Group Type: ACTIVE_COMPARATOR

Oseltamivir

Intervention Type: DRUG

standard (75 mg bid) or high-dose (225 mg bid) oseltamivir

High Dose Oseltamivir arm 225mg bid

High dose arm of the study

Group Type: EXPERIMENTAL

Oseltamivir

Intervention Type: DRUG

standard (75 mg bid) or high-dose (225 mg bid) oseltamivir

Interventions

Oseltamivir

standard (75 mg bid) or high-dose (225 mg bid) oseltamivir

Intervention Type: DRUG

Other Intervention Names

Tamiflu

Eligibility Criteria

Inclusion Criteria

1. Patients age 12 and older and 45 kg or more

2. Suspected or confirmed influenza (Appendix A)

3. Requirement for ICU admission due to respiratory distress or critical illness defined as one of:

1. Inspired oxygen need of >50% for at least 4 hours (For FiO2 for non-intubated patients see Appendix B)

2. mechanical ventilation

3. Patient is receiving inotrope or vasopressor

4. Negative b-HCG test or negative bedside urine test pending a confirmatory b-HCG test for pregnancy in women of childbearing age (12-60 years of age) will allow study entry

Exclusion Criteria

1. Inability to obtain consent

2. Patients receiving more than two doses of 150 mg or higher oseltamivir in 36 hours before study entry

3. Patients having received more than 3 doses of 75 mg oseltamivir immediately in 36 hours before study entry

4. Age less than 12 years, or age <16 and weight less than 45 kg

5. Unlikely to absorb enteral study drug (e.g. patients with partial or complete mechanical bowel obstruction, intestinal ischemia, infarction, and short bowel syndrome)

6. Known allergy or hypersensitivity to oseltamivir

7. Pregnancy or breast feeding

8. Previous enrollment in current study

9. Concurrent involvement in an RCT examining an antiviral agent including other neuraminidase inhibitors, interferon-a and/or ribavirin

10. Chronic renal failure requiring chronic hemodialysis

11. Severe chronic liver disease (Child-Pugh Score 11-15)

12. Anticipated death within 24 hours as judged by attending physician or local PI

13. Patient carrying "do not intubate" order (a "no CPR" or "no defibrillate" or "no chest compressions" order alone is allowed)

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hoffmann-La Roche

INDUSTRY

Sponsor Role: collaborator

University of Manitoba

OTHER

Sponsor Role: lead

Responsible Party

Winnipeg Regional Health Authority; Health Sciences Centre

Principal Investigators

Anand Kumar, MD

Role: PRINCIPAL_INVESTIGATOR

University of Manitoba

Locations

Winnipeg Regional Health Authority; Health Sciences Centre

Winnipeg, Manitoba, Canada

Countries

Canada

Other Identifiers

133312

Identifier Type: -

Identifier Source: org_study_id